Viromed Medical AG Stock
Price
Target price
€3.50
€3.50
-2.230%
-0.08
-2.230%
€7.00
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Viromed Medical
sharewise wants to provide you with the best news and tools for Viromed Medical, so we directly link to the best financial data sources.
Financials
News
EQS-Adhoc: Viromed Medical AG and HELLMUT RUCK GmbH have concluded an exclusive distribution agreement for plasma devices
EQS-Adhoc: Viromed Medical AG and HELLMUT RUCK GmbH have concluded an exclusive distribution agreement for plasma devices
EQS-Adhoc: Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care
EQS-Adhoc: Viromed confirms talks with an international MedTech company regarding a cooperation in the field of wound care
EQS-News: Viromed Medical AG: Reallocation of Viromed shares broadens investor base
EQS-News: Viromed Medical AG: Reallocation of Viromed shares broadens investor base
EQS-News: Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships
EQS-News: Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships
EQS-News: Viromed Medical AG launches in vivo and ex vivo study with cold plasma on living lungs
EQS-News: Viromed Medical AG launches in vivo and ex vivo study with cold plasma on living lungs
EQS-News: Viromed Medical AG initiates approval process for PulmoPlas® with the Federal Institute for Drugs and Medical Devices (BfArM)
EQS-News: Viromed Medical AG initiates approval process for PulmoPlas® with the Federal Institute for Drugs and Medical Devices (BfArM)
EQS-News: Viromed Medical AG: Successful ISO 13485 certification paves the way for market launch of ViroCAP® in October 2025
EQS-News: Viromed Medical AG: Successful ISO 13485 certification paves the way for market launch of ViroCAP® in October 2025
EQS-News: Viromed Medical AG: Annual General Meeting approves all proposed resolutions by a large majority
EQS-News: Viromed Medical AG: Annual General Meeting approves all proposed resolutions by a large majority
EQS-News: Viromed Medical AG enters into a distribution partnership with TriPart for the market launch of ViroCAP® and PulmoPlas® in Turkey
EQS-News: Viromed Medical AG enters into a distribution partnership with TriPart for the market launch of ViroCAP® and PulmoPlas® in Turkey
EQS-Adhoc: Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026
EQS-Adhoc: Viromed Medical AG expects dynamic growth and announces forecast for 2025 and 2026
EQS-News: Viromed Medical AG: Cold plasma technology shows potential to significantly reduce deaths in ventilated patients
EQS-News: Viromed Medical AG: Cold plasma technology shows potential to significantly reduce deaths in ventilated patients